Price (delayed)
$24.13
Market cap
$1.69B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.2
Enterprise value
$1.75B
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in
There are no recent dividends present for XNCR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.